Rxsight Inc is a healthcare technology company that focuses on enhancing vision correction through its innovative approach to personalized refractive surgery. The company develops advanced systems that utilize sophisticated algorithms and proprietary software to optimize intraocular lenses for patients undergoing cataract surgery. By combining data-driven insights with precision eye care, Rxsight aims to improve visual outcomes for patients, ultimately advancing the standards of treatment in the ophthalmic field. Their commitment to personalized medicine is reflected in their ongoing research and development efforts to create more effective solutions for vision-related challenges. Read More
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In RxSight (RXST) To Contact Him Directly To Discuss Their Options
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws.
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025, inclusive (the “Class Period”). RxSight investors have until September 22, 2025 to file a lead plaintiff motion.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025, inclusive (the “Class Period”). RxSight investors have until September 22, 2025 to file a lead plaintiff motion.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025. RxSight describes itself as a “commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses.”
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, inclusive.
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of (“RxSight” or the “Company”) (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Central District of California, captioned Makaveev v. RxSight, Inc., et al., Case No. 8:25-cv-01596, on behalf of persons and entities that purchased or otherwise acquired RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
The DJS Law Group announces that it is investigating claims on behalf of investors of RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) for violations of the securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) for violations of the securities laws.
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of (“RxSight” or the “Company”) (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RxSight, Inc. (NASDAQ: RXST) for potential violations of the federal securities laws.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith continues its investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors concerning the Company’s possible violations of federal securities laws.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In RxSight (RXST) To Contact Him Directly To Discuss Their Options
The Law Offices of Frank R. Cruz continues its investigation of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.
